Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 3 1Phase 2/3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 62Breast Neoplasms 44Prostatic Neoplasms 35Lung Neoplasms 29Multiple Myeloma 24Neoplasms 22Colorectal Neoplasms 19Parkinson Disease 4, Autosomal Dominant Lewy Body 18Ovarian Neoplasms 17Neoplasm Metastasis 17Leukemia, Lymphocytic, Chronic, B-Cell 17Carcinoma, Renal Cell 15Pancreatic Neoplasms 13Small Cell Lung Carcinoma 12Endometrial Neoplasms 12Urinary Bladder Neoplasms 10Stomach Neoplasms 10Squamous Cell Carcinoma of Head and Neck 10Leukemia, Myeloid, Acute 10Myasthenia Gravis 9Lymphoma, Follicular 9Fallopian Tube Neoplasms 9Non-Muscle Invasive Bladder Neoplasms 8Colonic Neoplasms 8Recurrence 7Burkitt Lymphoma 7Lymphoma, Mantle-Cell 6Esophageal Neoplasms 6Carcinoma 6Biliary Tract Neoplasms 6

Interventions

Temozolomide 1Radiation 1Photons 1Magnetic Resonance Spectroscopy 1Lomustine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Gliosarcoma × 30 days × Clear all
NCT05095376 2026-05-19

Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma

NRG Oncology

Phase 3 Active not recruiting
265 enrolled
CNSSarcoma

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡